JP Morgan Comments on Trial Completion of Baxter's Alzheimer's Drug

“We confirmed on Wednesday that the first of Baxter's

two phase III IVIG for Alzheimer's trials has now completed enrollment,” JP Morgan wrote in a report this morning. “An additional 30 patients were enrolled in the trial versus plan bringing total enrollment to 390 patients randomized to either (a) 400mg of IVIG/kg of bodyweight every 2 weeks; (b) 200mg of IVIG/kg; or (c) a placebo solution. Patients will be dosed and followed for 18 months with the last patient now expected to reach follow-up in January 2013. Given time for data gathering and analysis, we should see headline data by mid-2013.” Baxter closed Wednesday at $60.58.